Prognostic factors in children and adolescents with acute myeloid leukemia (exluding children with Down syndrome and acute promyelocytic leukemia): Univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821

Leukemia

Volumn 14, Issue 7, 2000, Pages 1201-1207

  Chang, M ^a   Raimondi, S C ^b   Ravindranath, Y ^c,h   Carroll, A J ^d   Camitta, B ^e   Gresik, M V ^f   Steuber, C P ^f   Weinstein, H ^g  

^a UNIVERSITY OF FLORIDA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Childhood acute myeloid leukemia; Prognostic factors; Recursive partitioning analysis

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL STRUCTURE; CHILD; CHROMOSOME 16; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; CYTOGENETICS; DATA ANALYSIS; DOWN SYNDROME; FEMALE; GENDER; HUMAN; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK; SURVIVAL RATE; TREATMENT FAILURE;

EID: 0033934583     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401832     Document Type: Article

References (30)

1. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn ML, Link M, Murphy S, Pui CH, Pullen J, Reamon G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Uniform approach to classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18-24.
2. Weinstein HJ, Mayer RH, Rosenthal DS, Coral FS, Camitta EM, Gelber RD. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 1983; 62: 315-319.
3. Steuber CP, Civin C, Krisher J, Culbert S, Ragab A, Ruymann FB, Ravindranath Y, Leventhal B, Wilkinson R, Vietti TJ. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study. J Clin Oncol 1991; 9: 247-258.
4. Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood 1990; 75: 1932-1940.
5. Creutzig U, Harbott J, Sperling C, Ritter J, Zimmermann M, Loftler H, Riehm H, Schellong G, Ludgwig WD. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 1995; 86: 3097-3108.
6. Woods WG, Kobrinsky N, Buckley J, Neudorf S, Sander J, Miller L, Barnard D, Benjamin D, DeSwarte J, Kalousek D. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Children's Cancer Group pilot study. J Clin Oncol 1993; 11: 1448-1457.
7. Ravindranath V, Steuber CP, Krischer J, Civin CI, Ducore J, Vega R, Pitel P, Inoue S, Bleher R, Sexauer C. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. J Clin Oncol 1991; 9: 572-580.
8. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, Carroll A, Inoue S, Camitta B, Weinstein HJ. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. New Engl J Med 1996, 334: 1428-1434.
9. Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S, Gold S, Barnard DR, DeSwarte J, Dusenbery K, Kalousek D, Arthur DC, Lange BJ. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from Children's Cancer Group. Blood 1996; 87: 4979-4989.
10. Hann I, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG, Burnett AK. Randomized comparison of DAT versus ADE as induction chemotherapy in children and adults with acute myeloid leukemia. Results of the Medical Research Council's AML trial (MRC AML-10). Adult and Childhood Working Parties of the Medical Research Council. Blood 1997; 89: 2311-2318.
11. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, Chauvenet A, Alvarado CS, Dubowy R, Pitchery AK. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992; 80: 2210-2214.
12. Degos L, Dombret H, Chomianne C, Daniel MT, Midea JM, Chaslang C, Castaigne S, Fenaux P. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643-2653.
13. Bloomfield CD, Lawrence D, Byrd JC, Carrol A, Pettenati MJ, Tantravahi R, Patil SR, Davey PR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173-4179.
14. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importante of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML, 10 trial. The Medical Research Council Adult and Children's Leukemia working Parties. Blood 1998; 7: 2322-2333.
15. Raimondi SC, Chang MN, Ravindranath Y, Behm FG, Gresik MV, Steuber CP, Weinstein HJ, Carroll AJ for the Pediatric Oncology Group. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome a cooperative Pediatric Oncology Group study - POG 8821. Blood 1999; 94: 3707-3716.
16. Ciampi A, Hogg SA, Kates L. Stratification by stepwise regression, correspondence, analysis, and recursive partitioning: a comparison of three methods of survival analysis with covariates. Comput Stat Data Anal 1986; 4: 183-204.
17. Shuster JJ, Falletta JM, Pullen DJ, Crist WM, Humphrey CB, Dowell BL, Wharam MD, Borounitz M. Prognostic factors in children with T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990; 75: 166-173.
18. Harris MB, Shuster JJ, Carroll A, Look AT, Borowitz MJ, Crist WM, Nitschke R, Pullen J, Steuber CP, Land VJ. Trisomy of leukemic cell chromosomes 4 and 10 identities children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood 1992; 79: 3316-3324.
19. Cox DR. Regress on models and life-tables. JR Stat Sec B 1992; 34: 187-220.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 475-481.
21. Lie SO, Jonmundsson G, Mellander L, Silimes MA, Yssing M, Gustafsson G. A population-based study of 272 children with acute myeloid leukemia treated on two consecutive protocols with different intensity: best outcome in girls, infants and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol 1996; 94: 82-88.
22. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne del'Adulto (GIMEMA) Leukemia Cooperative Groups. New Engl J Med 1995; 332: 217-223.
23. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich FJ. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1998; 2: 403-412.
24. Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, Howells WB, Gold S, Sanders J, Neudori S, Smith FO, Woods WG. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group studies 2861 and 2891. Blood 1998; 91: 608-615.
25. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. New Engl J Med 1999; 341: 1051-1062.
26. Wang J, Hoshino T, Redner R, Kajigaya S, Liu J. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-Cor/mSin3/HDACI complex. Proc Natl Acad Sci USA 1998; 95: 10860-10865.
27. Shurtleff SA, Buijs A, Behm FG, Rubinitz JE, Raimondi SC, Hancock ML, Chan GC, Pui CH, Grosveld G, Downing JR. Tel/AML1 fusion resulting from cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985-1989.
28. Taub J, Huang X, Matherly L, Stout M, Buck S, Massey G, Becton D, Chang M, Weinstein H, Ravindranath Y. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between down syndrome and non-down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 1999; 94: 1383-1400.
29. Wang J, Saunthararajah Y, Redner R, Liu J. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AMLI-ETO leukemia cells. Cancer Res 1999; 59: 2766-2769.
30. Kosugi H, Towatari M, Hatano S, Kitamura K, Kiyo H, Kinoshita T, Tanimoto M, Murate T, Kawashima K, Saito H, Naoe T. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia 1999; 13: 1316-1327.